Insider · CIK 0002032345
Khurram Jamil
Files at GALT (GALECTIN THERAPEUTICS INC). First filing Dec 26, 2024, latest Jun 30, 2026.
Khurram Jamil files SEC Form 4 as officer at GALT (GALECTIN THERAPEUTICS INC). Since Dec 26, 2024, Khurram Jamil has reported 0 open-market buys worth $0 and 8 open-market sells worth $1.4M, the latest filed on Jun 30, 2026.
A track record needs three past buys with six months of prices behind them; Khurram Jamil has 0, so none is measured yet.
The newest scored trade: sold $262k of GALT on Jun 26, 2026, filed Jun 30, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 7 sells worth $1.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GALT: GALECTIN THERAPEUTICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | GALECTIN THERAPEUTICS INC | $262k 52,037 shares | -2555% | +140% from low-23% from high | |
| 8Weak | GALECTIN THERAPEUTICS INC | $24k 7,557 shares | -100% | +50% from low-52% from high | |
| 0Weak | GALECTIN THERAPEUTICS INC | $1,761 568 shares | -100% | +125% from low-57% from high | |
| 28Weak | GALECTIN THERAPEUTICS INC | $232k 60,000 shares | -100% | +268% from low-38% from high | |
| 21Weak | GALECTIN THERAPEUTICS INC | $33k 8,125 shares | -100% | +278% from low-36% from high | |
| 26Weak | GALECTIN THERAPEUTICS INC | $137k 19,442 shares | -434% | +670% from low-1% from high | |
| 35Weak | GALECTIN THERAPEUTICS INC | $663k 121,117 shares | -460% | +558% from low-8% from high | |
| 5Weak | GALECTIN THERAPEUTICS INC | $12k 13,654 shares | -34% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 31, 2025 | GALT GALECTIN THERAPEUTICS INC | 8,125 0.01% of outstanding | $33k | Dec 31, 2025 | $799k |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | 21,479 0.03% of outstanding | $151k | Dec 17, 2025 | $662k |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | 121,117 0.19% of outstanding | $660k | Nov 13, 2025 | none |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | 13,654 0.02% of outstanding | $14k | Dec 23, 2024 | none |
Transactions
Every row this insider has filed, 47 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +2,037 | $2.20 | $4,481 | 2,037 | Jun 30, 2026 |
| Jun 26, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -2,037 | $5.00 | $10k | 0 | Jun 30, 2026 |
| Jun 26, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +2,533 | $2.50 | $6,333 | 2,533 | Jun 30, 2026 |
| Jun 26, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -2,533 | $5.00 | $13k | 0 | Jun 30, 2026 |
| Jun 29, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +47,467 | $2.50 | $119k | 47,467 | Jun 30, 2026 |
| Jun 29, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -47,467 | $5.04 | $239k | 0 | Jun 30, 2026 |
| Jun 26, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -2,037 | $0.00 | $0 | 100,000 | Jun 30, 2026 |
| Jun 26, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,533 | $0.00 | $0 | 47,467 | Jun 30, 2026 |
| Jun 29, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock Option (right to buy)derivative10b5-1 | -47,467 | $0.00 | $0 | 0 | Jun 30, 2026 |
| Jun 23, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +7,557 | $1.23 | $9,295 | 7,557 | Jun 25, 2026 |
| Jun 23, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -7,557 | $3.14 | $24k | 0 | Jun 25, 2026 |
| Jun 23, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -7,557 | $0.00 | $0 | 32,500 | Jun 25, 2026 |
| May 26, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +568 | $1.23 | $699 | 568 | May 28, 2026 |
| May 26, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -568 | $3.10 | $1,761 | 0 | May 28, 2026 |
| May 26, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -568 | $0.00 | $0 | 40,057 | May 28, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative10b5-1 | +65,000 | $0.00 | $0 | 65,000 | Jan 21, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Restricted Stock Unitderivative10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Jan 6, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -13,055 | $4.20 | $55k | 46,945 | Jan 6, 2026 |
| Jan 5, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -25,499 | $3.90 | $99k | 21,446 | Jan 6, 2026 |
| Jan 6, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -21,446 | $3.65 | $78k | 0 | Jan 6, 2026 |
| Jan 1, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Dec 31, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +8,125 | $1.23 | $9,994 | 8,125 | Jan 5, 2026 |
| Dec 31, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -8,125 | $4.07 | $33k | 0 | Jan 5, 2026 |
| Dec 31, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -8,125 | $0.00 | $0 | 40,625 | Jan 5, 2026 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -4,479 | $7.04 | $32k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +6,463 | $2.20 | $14k | 6,463 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -6,463 | $7.04 | $45k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +8,500 | $2.50 | $21k | 8,500 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -8,500 | $7.04 | $60k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -6,463 | $0.00 | $0 | 102,037 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -8,500 | $0.00 | $0 | 50,000 | Dec 19, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -21,867 | $5.47 | $120k | 4,479 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +41,500 | $2.20 | $91k | 45,979 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -41,500 | $5.47 | $227k | 4,479 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +41,500 | $2.50 | $104k | 45,979 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -41,500 | $5.47 | $227k | 4,479 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +16,250 | $1.23 | $20k | 20,729 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -16,250 | $5.47 | $89k | 4,479 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -41,500 | $0.00 | $0 | 108,500 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -41,500 | $0.00 | $0 | 58,500 | Nov 14, 2025 |
| Nov 13, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -16,250 | $0.00 | $0 | 48,750 | Nov 14, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock Option (right to buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Jan 27, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Restricted Stock Unitderivative | +60,000 | $0.00 | $0 | 60,000 | Jan 27, 2025 |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +40,000 | $0.00 | $0 | 40,000 | Dec 26, 2024 |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -13,654 | $0.88 | $12k | 26,346 | Dec 26, 2024 |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Restricted Stock Unitsderivative10b5-1 | +40,000 | $0.00 | $0 | 0 | Dec 26, 2024 |
Questions about Khurram Jamil
Answered from the filings on this page, as of the latest one.
Is Khurram Jamil buying or selling?
In the last 12 months Khurram Jamil reported 0 open-market buys worth $0 and 7 open-market sells worth $1.4M on SEC Form 4; the latest was sold $262k of GALT on Jun 26, 2026. Grants, option exercises and tax withholding are not counted.
How did Khurram Jamil's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Khurram Jamil has 0.
Where does Khurram Jamil file Form 4?
Khurram Jamil has filed Form 4 at GALT (GALECTIN THERAPEUTICS INC) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.